Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 27Genitourinary 11Gynecologic 8Dermatologic 3CNS 2Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Melanoma 3Sarcoma 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Dactinomycin × Dermatologic × Clear all
NCT01323517 2018-05-15

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
26 enrolled 11 charts
Dermatologic

Melanoma

NCT01531244 2014-07-18

Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma

Washington University School of Medicine

Phase 1/2 Withdrawn
Dermatologic

Melanoma

NCT00004250 2013-01-16

Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
35 enrolled
DermatologicSarcoma

Melanoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡